PF-3450074

CAS No. 1352879-65-2

PF-3450074( PF3450074 | PF-74 | PF74 )

Catalog No. M11434 CAS No. 1352879-65-2

PF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 39 Get Quote
10MG 71 Get Quote
25MG 120 Get Quote
50MG 203 Get Quote
100MG 357 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PF-3450074
  • Note
    Research use only, not for human use.
  • Brief Description
    PF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells.
  • Description
    PF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro; acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells, induced the rapid dissolution of the HIV-1 capsid; PF74 antiviral activity is promoted by binding of the host protein cyclophilin A to the HIV-1 capsid, and PF74 and cyclosporine exhibited mutual antagonism.
  • In Vitro
    PF-3450074 (PF-74) exhibits anti-viral activities against HIV wild type NL4-3 andHIV T107N mutant with EC50 values of 0.72 μM and 4.5μM, respectively.PF-3450074 (PF-74) displays a good potency in primary human peripheral blood mononuclear cells (PBMCs), inhibits HIV-193RW025, HIV-1JR-CSF and HIV-193MW965 with IC50 values of 1.5 ± 0.9 μM; 0.6 ± 0.20 μM; and 0.6 ± 0.10 μM, respectively. This compound shows Median IC50?and CC50?values of 0.9 ± 0.5 μM and 90.5 ± 5.9 μM, respectively.The KD?for the interaction between?PF-74?and the CA hexamer, derived in the same manner as for NUP153, is determined to be 176 ± 78 nM.PF-3450074 (PF-74) (10 μM; 8 hours) results in a marked reduction in late products of reverse transcription in HeLa-P4 cells with DNase I-treated stocks of Env-defective HIV-1 (R9.Env-). RT-PCR Cell Line:HeLa-P4 cells Concentration:10 μMIncubation Time:8 hours Result:Inhibited HIV-1 reverse transcription in target cells.
  • In Vivo
    ——
  • Synonyms
    PF3450074 | PF-74 | PF74
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1352879-65-2
  • Formula Weight
    425.532
  • Molecular Formula
    C27H27N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (587.52 mM)
  • SMILES
    O=C(N[C@@H](CC1=CC=CC=C1)C(N(C)C2=CC=CC=C2)=O)CC3=C(C)NC4=C3C=CC=C4
  • Chemical Name
    2-Methyl-N-[(1S)-2-(methylphenylamino)-2-oxo-1-(phenylmethyl)ethyl]- 1H-indole-3-acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Shi J, et al. J Virol. 2011 Jan;85(1):542-9. 2. Shi J, et al. J Virol. 2015 Jan;89(1):208-19. 3. Zhou J, et al. J Virol. 2015 Sep;89(17):9068-79. 4. Saito A, et al. J Virol. 2016 May 27;90(12):5808-5823.
molnova catalog
related products
  • N.41

    N.41 (HIV inhibitor N.41, Vif inhibitor N.41) is a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G (A3G) protein (IC50=2.2 uM).

  • DPC-681

    A potent and selective inhibitor of HIV-1 protease with IC90 of 4-40 nM.

  • DRB

    DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM).